On March 11, 2020 AskAt’s reported Frontiers in Immunology, an international scientific journal focusing on immunology, cancer immunity and immunotherapy, has published review article describing a mechanism of anti-tumor action of the EP4 antagonist (Press release, AskAt, MAR 11, 2020, View Source [SID1234555398]). The review is based on immuno-oncological evidence recently published in scientific journals. It suggests a new concept for the mechanism of action of the EP4 antagonist, in combination with a cancer-immunity cycle theory, demonstrating a position for the therapy within current cancer immunotherapy. This new concept helps to advance understanding of AskAt’s EP4 antagonists, AAT-007 and AAT-008, in cancer immunotherapy, and provides an immunological background of EP4 antagonist therapy in combination with immune checkpoint inhibitors, chemotherapy, and tumor radiotherapy. Currently, AAT-007 and AAT-008 are being developed in the U.S. and China, initially targeting colorectal cancer and non-small cell lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!